Iceland· IS-EU/1/15/1025/001-002

Evotaz

A atazanavir and cobicistat product containing atazanavirum inn súlfat,cobicistatum inn, registered in Iceland by Bristol-Myers Squibb Pharma EEIG*. The same ATC class is registered in 11 of our 19 countries.

ATC J05AR15

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedEvotazATCJ05AR15REGISTER NO.IS-EU/1/15/1025/001-0…PACKS LISTED0CHECKEDSeptember 29, 2026

Where it is registered

Atazanavir and cobicistat is registered in 11 of 19 countries.

Countries holding a registration under ATC J05AR15 (atazanavir and cobicistat), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 7 of them publish a price we can compare per daily dose

Atazanavir and cobicistat · ATC J05AR15

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Spainprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Atazanavirum INN súlfat,Cobicistatum INN
Manufacturer
Bristol-Myers Squibb Pharma EEIG*
Country
Iceland (IS)
ATC code
J05AR15
ATC class
Atazanavir and cobicistat
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ddbe49d0-cbfe-4f13-a7ae-34b15fb2018b
GET /v1/drugs/ddbe49d0-cbfe-4f13-a7ae-34b15fb2018b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmuhúðuð tafla",
  "source": "lyfjastofnun",
  "atc_raw": "J05AR15",
  "marketed": false,
  "strength": "300 mg/150 mg",
  "ma_number": "EU/1/15/1025/001-002",
  "substance": "Atazanavirum INN súlfat,Cobicistatum INN",
  "other_info": "Ávísun lyfsins er bundin við sérfræðinga í smitsjúkdómum.",
  "legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
  "ma_issued_serial": "42198"
}

See everything about atazanavir and cobicistat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.